PMOS Does Not Stop at Menopause. But the Story Does Not Have to End There Either.

What happens when you carry this metabolic pattern into midlife — and what a whole-body approach actually changes.

Perimenopause has a way of making the invisible visible.

Weight shifting to the abdomen when nothing else changed. Blood sugar stability that was always a bit unreliable, suddenly harder to manage. Sleep that used to be adequate, now fragmented. Anxiety that arrives without a clear cause. A body that feels unfamiliar in ways that are difficult to explain and even harder to have taken seriously.

For many women, these are framed as perimenopausal symptoms. And they are. But for the woman who has been carrying the PMOS metabolic pattern — diagnosed or not — they are also something else: the unmistakable surfacing of a metabolic reality that has been present for years, sometimes decades, finally becoming impossible to ignore.

This post is for that woman.

It is for the woman who was never diagnosed but recognises the pattern. The woman who was diagnosed with PCOS years ago and given the pill and sent on her way. The woman in perimenopause who is doing everything right and still not feeling right. And the woman who has been managing symptoms for so long that she has stopped expecting to feel genuinely well.

Because here is what the research is clear about: the metabolic driver of PMOS is modifiable. When you address it properly, much of what it has been driving can improve significantly. That is not optimistic language. That is what the evidence shows.

PMOS does not retire at menopause

This is one of the most underacknowledged facts in women's health: PMOS is a lifelong metabolic condition. It does not resolve when menstruation stops. Researchers at Florida Atlantic University, in a scoping review specifically focused on PMOS in midlife and beyond, noted that women in perimenopause and post-menopause remain dramatically underrepresented in PMOS research and treatment studies — meaning this population has been systematically left out of the conversation.

The hormonal shifts of perimenopause — declining oestrogen, fluctuating progesterone, rising FSH — do not neutralise the metabolic pattern. They amplify it. Oestrogen plays a protective role in insulin sensitivity. As it declines, insulin resistance worsens. Blood sugar stability deteriorates. Sleep architecture disrupts. Inflammatory tone rises. Cardiovascular risk compounds.

In a woman without PMOS, this transition brings challenges. In a woman who has been carrying the PMOS metabolic signature, it brings all of that — but more intensely, more rapidly, and with higher downstream risk.

What the metabolic picture looks like in midlife

•          Insulin resistance that worsens as oestrogen declines — the protective buffer is removed

•          Progressive blood sugar dysregulation, increasing risk of impaired glucose tolerance and type 2 diabetes

•          Elevated cardiovascular risk — arterial calcification, carotid thickening, endothelial dysfunction, elevated blood pressure

•          Non-alcoholic fatty liver disease (now called MASLD) — driven by excess insulin, impaired glucose metabolism, and androgen excess

•          Persistent androgen symptoms — hirsutism, hair thinning — continuing well into midlife and beyond, particularly in hyperandrogenic phenotypes

•          Chronic low-grade inflammation — elevated CRP, homocysteine, inflammatory cytokines — underlying joint pain, brain fog, mood instability, and fatigue

A large Australian retrospective study found that women with PMOS had significantly elevated risk of cerebrovascular disease, ischaemic heart disease, and arterial and venous disease compared to controls. These risks were not confined to overweight women. They were present in lean women too. And they began younger.

This is not meant to alarm. It is meant to be clear. Because clarity is the beginning of action — and action, at this stage, makes a substantial difference.

The hopeful part — and it is genuinely hopeful

Insulin resistance is not a life sentence. It is a modifiable condition. And when insulin resistance improves, the downstream effects that it drives improve with it.

Androgen levels drop as excess insulin stops overstimulating ovarian and adrenal testosterone production. Inflammatory markers reduce. Energy stabilises. Sleep improves. Cognitive clarity returns. Weight distribution begins to shift. Skin symptoms frequently improve. For women who still have cycles, cycle regularity often improves.

This is the argument for a metabolic-first approach, and it is a compelling one: treat the driver, and many of the downstream symptoms resolve with it. Not all of them, not overnight, not without effort. But the direction of change is real and it is consistent.

What a whole-body metabolic approach actually involves

It starts with knowing what you are working with. And for PMOS, that means testing that goes beyond the standard hormone panel.

The testing that reveals the real picture

•          Fasting insulin — not included in standard blood panels, but the single most important marker for assessing insulin resistance status

•          HOMA-IR — calculated from fasting glucose and fasting insulin; the most practical clinical measure of insulin sensitivity

•          Full lipid panel — including triglycerides and HDL ratio, not just total cholesterol

•          High-sensitivity CRP — for chronic inflammatory status

•          Vitamin D, magnesium, and zinc levels — deficiencies in all three are common in PMOS and compound metabolic and hormonal dysfunction

•          Full reproductive and adrenal hormone panel — testosterone, DHEAS, cortisol, thyroid function

For women who want an even deeper picture, Hair Tissue Mineral Analysis (HTMA) adds a layer that standard blood panels cannot. It reveals the mineral patterns, the adrenal and thyroid axis status, and the chronic stress physiology that are frequently present in PMOS — the slow metabolic compensation that has been running quietly in the background for years. It is one of the most useful tools I have in clinical practice for women with complex, long-standing presentations.

Nutrition that addresses the root driver

The most powerful dietary lever in PMOS is reducing insulin load. This is not a crash diet or an extreme protocol. It is a considered shift:

•          Lower glycaemic eating — reducing the speed and magnitude of blood glucose rises, which reduces the insulin response that drives androgen excess

•          Reduced refined carbohydrates, grains, and added sugars — progressively removing the primary drivers of insulin elevation

•          Protein-first eating — stabilises blood glucose, reduces hunger driven by insulin dysregulation, and supports the muscle mass that is critical for insulin sensitivity

•          Anti-inflammatory nutrition — omega-3 fatty acids, phytonutrient-rich vegetables, minimising ultra-processed foods

A 2025 meta-analysis of 12 clinical trials found that low-carbohydrate and ketogenic approaches in women with PMOS successfully reduced insulin resistance, lowered androgens, and improved weight markers. The evidence base is building. The mechanism is clear.

Movement as metabolic medicine

Physical activity — particularly resistance training — improves insulin sensitivity at the cellular level, independently of weight loss. This is important: you do not need to lose weight for movement to improve your metabolic picture. The cellular effects of resistance training on glucose uptake are real and measurable regardless of body composition changes. It is one of the most accessible metabolic tools available, and it is consistently underutilised in conventional PMOS management.

Targeted nutritional support

•          Inositol (myo-inositol and D-chiro-inositol) — well-evidenced as an insulin sensitiser in PMOS, with effects in the research that are comparable to metformin

•          Magnesium — widely deficient in women with PMOS; plays a critical role in insulin receptor function and glucose metabolism

•          Vitamin D — deficiency is common and associated with worsened insulin resistance and inflammation

•          Omega-3 fatty acids — reduce inflammatory cytokines, improve lipid profiles, and support hormonal signalling

•          Zinc — supports androgen metabolism and skin health

•          Adaptogenic herbs — for adrenal resilience and cortisol regulation, which directly compound insulin resistance when dysregulated

The stress-cortisol-insulin connection

Chronic stress and dysregulated cortisol are not separate from the PMOS picture — they are part of it. Cortisol raises blood glucose, which stimulates insulin. It also directly stimulates ovarian and adrenal androgen production. Women with PMOS frequently carry elevated cortisol alongside adrenal androgen excess, a pattern that is rarely captured when only reproductive hormones are tested.

Addressing adrenal resilience — sleep quality, nervous system regulation, stress physiology — is not a wellness add-on. It is a core component of metabolic management in this condition.

This is relevant at every age — including your daughter's

A whole-body metabolic approach to PMOS carries benefit across the entire lifespan — not just for women in midlife.

For adolescents and younger women, early metabolic intervention is the single greatest opportunity to alter the long-term trajectory. The insulin resistance that seems manageable at twenty-five becomes the diabetes risk at fifty, the cardiovascular risk at sixty. Catching the pattern early and addressing it properly reduces compound interest on a condition that accumulates over decades.

If you are a mother reading this and something in the symptom picture resonated for your daughter — irregular periods, skin changes, energy and mood instability, difficulty with weight — it is worth having the full metabolic picture assessed. Not just reproductive hormones. The metabolic picture.

For women in perimenopause and beyond: this is a critical window. The metabolic-first approach at this stage directly reduces the severity of perimenopausal symptoms, protects long-term cardiovascular and cognitive health, and provides the metabolic stability that allows women to age powerfully — with full understanding of what has been driving their experience, often for years before anyone named it.

Where to go from here

If you have read through this series and you are ready to understand your own picture properly — not symptoms in isolation, but the metabolic pattern underneath — a Foundational Health Assessment is where that conversation starts.

It is a full clinical consultation. Your history, your current symptoms, your testing, your goals. The beginning of an approach that treats your metabolic health as the foundation everything else sits on — because for women with PMOS, that is exactly what it is.

Book a Foundational Health Assessment →

I am also developing a dedicated course for women who want to go deep on metabolic health — covering exactly the territory this series has opened up. If you want to be the first to hear about it, make sure you are on the newsletter.

Subscribe to the Foxy For Life newsletter →

Cherice

Frequently Asked Questions

Does PMOS improve or resolve after menopause?

No. The metabolic dysfunction that drives PMOS does not resolve at menopause. In many women it worsens, because oestrogen — which plays a protective role in insulin sensitivity — declines during perimenopause. The hormonal shifts of this transition amplify existing metabolic patterns, increasing insulin resistance, cardiovascular risk, and inflammatory load. Women who have carried unmanaged PMOS into midlife require active metabolic management, not observation.

I am in perimenopause and my symptoms have got significantly worse. Could PMOS be part of this?

Possibly, and it is worth investigating. The symptoms of perimenopause — weight gain around the abdomen, worsening blood sugar stability, disrupted sleep, heightened anxiety, cognitive changes — overlap significantly with the PMOS metabolic picture. In women who have been carrying this pattern, the hormonal shifts of perimenopause amplify it. The two are not mutually exclusive; in many women, they are the same underlying pattern made more visible by hormonal transition.

What is HOMA-IR and why does it matter?

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculation derived from fasting glucose and fasting insulin levels. It provides a practical clinical measure of insulin resistance status — far more informative than fasting glucose alone, which can be entirely normal in a woman with substantial underlying insulin resistance. It is a straightforward, inexpensive calculation that is simply not included in standard panels. Requesting both fasting insulin and fasting glucose from your GP allows the calculation to be made.

What is Hair Tissue Mineral Analysis and is it relevant to PMOS?

Hair Tissue Mineral Analysis (HTMA) is a functional test that measures mineral levels and ratios in hair tissue, providing a picture of mineral status, metabolic function, and adrenal and thyroid axis patterns over the preceding months. In women with PMOS, it frequently reveals the chronic stress physiology, depleted mineral reserves, and metabolic compensation patterns that standard blood panels do not capture. It is particularly useful for women with complex or long-standing presentations, and for those whose standard testing has consistently come back 'normal' despite persistent symptoms.

I have been managing PCOS symptoms for years. Is it too late for a metabolic approach to make a difference?

No. Insulin resistance is modifiable at any age. The trajectory of PMOS is not fixed — it is influenced by the care it receives. Women who address the metabolic root of the condition in midlife — even after years of symptom-only management — see meaningful improvements in energy, weight distribution, inflammatory markers, cardiovascular risk factors, and quality of life. The earlier you begin, the greater the benefit, but beginning at any stage is worthwhile.